You Can Stick to a Training Plan. Why Is Everyday Focus So Much Harder?

Your training log is immaculate. Every session for the past year is recorded: sets, reps, rest periods, how the last set felt. You have followed periodized programs that most people abandon in week three.

The email that needs two sentences has been open for four days.

If that contrast sounds familiar, it is worth understanding properly rather than writing off as a character flaw. The gap between what you can do under structure and what slips away in unstructured daily life has real explanations, and some of them deserve professional attention rather than another productivity app.

This article is about what attention actually is, what ADHD involves, which approaches have genuine evidence behind them, and why the peptide headlines circulating in fitness spaces do not answer the question you are really asking.

Focus is a set of skills, not a dial

"Focus" sounds like one thing. Cognitively, it is several separate abilities that can fail independently:

• Task initiation — starting the thing, especially when it is boring or ambiguous.
• Working memory — holding information in mind long enough to use it: the instruction you just read, the reason you opened the browser.
• Distraction filtering — letting the notification exist without obeying it.
• Sustained attention — staying with a task past the point where it stops being novel.

Training often bypasses the hardest of these. A written program initiates the task for you. The gym has one obvious next action. Effort is physical and immediately visible. Everyday life offers none of that scaffolding—so a person can be genuinely disciplined in one arena and genuinely struggle in another, without either fact cancelling the other.

What ADHD is—and what it is not

Attention-deficit/hyperactivity disorder is a clinical diagnosis, not a vibe. According to the U.S. National Institute of Mental Health, ADHD involves a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. Symptoms begin in childhood, appear across more than one setting, and are assessed by qualified clinicians who also rule out other explanations—sleep problems, anxiety, depression, thyroid disease, medication effects and more.

Two implications matter here. First, being good at structured training neither proves nor rules out ADHD; plenty of diagnosed adults are excellent in high-stimulation, clearly-scaffolded environments and fall apart in open-ended ones. Second, struggling to answer emails is not a diagnosis either. Context, history and pervasiveness are what separate a rough season from a clinical condition—which is exactly why self-prescribing from a forum thread is the wrong tool.

What already has real evidence

If everyday focus is genuinely impairing your life, the options with actual clinical evidence are not exotic. A clinical overview published in the New England Journal of Medicine in October 2026 describes how adult ADHD is evaluated and the conventional options clinicians reach for. These include:

• Stimulant medications, the most studied pharmacological treatment, prescribed and monitored by a clinician.
• Non-stimulant options such as atomoxetine, which works differently and has its own evidence base, benefits and side-effect profile.
• Structured psychological treatment, including cognitive behavioral therapy adapted for ADHD, which targets the organizational and initiation problems directly.
• Sleep, exercise and routine—not treatments for ADHD itself, but factors that measurably affect attention in everyone and are worth fixing first or alongside.

None of this is a recommendation for you personally; that conversation belongs with a clinician who can actually evaluate you. And if you would rather not take a stimulant, that is a legitimate preference to raise, not a dead end—non-stimulant medications and behavioral support have their own evidence and can be discussed on their merits. The point is narrower: real options exist, and they are studied in the relevant population.

Semax: one small experiment, not an ADHD answer

Semax is a synthetic peptide fragment related to a naturally occurring hormone sequence, developed in Russia and discussed online as a "nootropic." The human evidence most often cited is a small experiment from the 1990s in which 16 healthy male workers received Semax over two days, with measures of attention under fatigue.

Read that description again: sixteen people, two days, no ADHD participants, no comparison to established treatments, published decades ago with little independent replication. Evidence level — very limited human data: it hints the compound can affect short-term attention measures in a narrow setting. What it does not establish: benefit for ADHD, for everyday executive function, or for anyone over weeks or months. This article is a non-exhaustive editorial review rather than a systematic literature search; within the cited studies, nothing establishes Semax's clinical effectiveness for adult ADHD.

Selank: an anxiety study, not an attention study

Selank is another Russian-developed synthetic peptide with a similar online reputation. The most relevant human citation is a small 2014 comparison involving 60 adults with anxiety-related conditions, with phenazepam as the comparator. The accessible English abstract does not establish blinded randomized evidence, the outcomes concerned anxiety rather than cognition, and the population was not adults with ADHD.

Anxiety and attention interact; untreated anxiety wrecks concentration. But a small anxiety-focused comparison cannot tell us whether Selank improves attention or helps with adult ADHD, or what long-term use looks like. It answers its own question, in its own population, with real limitations.

GLP-1 headlines and impulsivity

A 2025 randomized trial of tirzepatide in 114 adults over six weeks, published in Nature Medicine, measured appetite and cravings as primary outcomes, with some secondary measures touching on impulsivity. Fitness and biohacking spaces sometimes cite studies like this as if they speak to attention or ADHD.

They do not. This was not an ADHD trial; the participants, the outcomes and the timeframe were about appetite and eating behavior. Approved GLP-1 medicines are prescription drugs for specific indications, not over-the-counter focus tools—and obtaining them as "research use only" materials is not a loophole around that. The cited studies do not establish clinical effectiveness of GLP-1 medicines for adult ADHD.

The quality and safety problem nobody puts in the headline

Even setting efficacy aside, there is a material question. The U.S. Food and Drug Administration has flagged that certain bulk drug substances used in compounding, including Semax and Selank, may present significant safety risks. Neither is an FDA-approved medicine. A vial sold as "research use only" is a laboratory material, not a lower grade of medical authorization, and no label wording changes what is actually inside it.

The skill you already have

Here is the useful reframe. If you read training studies—if you have ever asked "how many subjects, what was the control, what did they actually measure"—you already own the exact skill this topic demands. Apply it identically:

• Sixteen workers for two days is not an ADHD trial.
• An open anxiety study is not an attention study.
• An appetite trial with a secondary impulsivity measure is not an executive-function result.

Our guide to how cell, animal and human studies differ walks through these tiers, and the beginner's guide to peptide research labels explains what research-use materials are and are not. The bar for evidence does not drop because the claim is exciting.

Where this leaves you

If the email has been open for four days, the most evidence-backed next step is unglamorous: describe the pattern honestly to a qualified clinician, including how long it has been there and where else it shows up. Whether the answer is ADHD, sleep debt, anxiety or simply an unstructured week, that evaluation is the path that actually branches toward treatments with data behind them.

Peptide research is genuinely interesting, and we will keep covering it carefully. But a research catalog is not a treatment plan, and research-use materials are not for human use. Recomp Report is published by The Peptide Gallery, LLC, the team behind TPG Bioscience, an affiliated research-products business; that relationship is disclosed wherever it appears and does not turn laboratory materials into personal medicine. Bring the curiosity. Keep the lanes separate.